Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer
- 524 Downloads
Several observational studies suggest that metformin reduces incidence cancer risk; however, many of these studies suffer from time-related biases and several cancer outcomes have not been investigated due to small sample sizes.
We constructed a propensity score-matched retrospective cohort of 84,434 veterans newly prescribed metformin or a sulfonylurea as monotherapy. We used Cox proportional hazard regression to assess the association between metformin use compared to sulfonylurea use and incidence cancer risk for 10 solid tumors. We adjusted for clinical covariates including hemoglobin A1C, antihypertensive and lipid-lowering medications, and body mass index. Incidence cancers were defined by ICD-9-CM codes.
Among 42,217 new metformin users and 42,217 matched-new sulfonylurea users, we identified 2,575 incidence cancers. Metformin was inversely associated with liver cancer (adjusted hazard ratio [aHR] = 0.44, 95% CI 0.31, 0.64) compared to sulfonylurea. We found no association between metformin use and risk of incidence bladder, breast, colorectal, esophageal, gastric, lung, pancreatic, prostate, or renal cancer when compared to sulfonylurea use.
In this large cohort study that accounted for time-related biases, we observed no association between the use of metformin and most cancers; however, we found a strong inverse association between metformin and liver cancer. Randomized trials of metformin for prevention of liver cancer would be useful to verify these observations.
KeywordsDiabetes mellitus Metformin Cancer Sulfonylureas
This work was supported under Contract No. 290-05-0042 from the Agency for Healthcare Research and Quality, US Department of Health and Human Services as part of the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) program. This project was additionally supported by National Institutes of Health (P20 DK090874-01) and in part by the by VA Clinical Science research and Development investigator-initiated grant CX000570-01 (Roumie). Dr. Murff was supported in part by R01CA143288 and R01CA160938 from the National Cancer Institute. Dr. Roumie was also supported in part by Center for Diabetes Translation Research P30DK092986. Dr. Hung (2-031-09S) was supported by a VA Career Development Award. Dr. Grijalva was supported in part by R01AG043471 from the National Institute on Aging. Support for Veterans Affairs/Centers for Medicare & Medicaid Services data was provided by the Department of Veterans Affairs, Veterans Affairs Health Services Research and Development Service, Veterans Affairs Information Resource Center (Project Nos. SDR 02-237 and 98-004).
Compliance with ethical standards
Conflict of interest
The authors declared that they have no conflicts of interest to disclose.
- 14.Wang Z, Lai ST, Xie L, Zhao JD, Ma NY, Zhu J, Ren ZG, Jiang GL (2014) Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diab Res Clin Pract 106(1):19–26. https://doi.org/10.1016/j.diabres.2014.04.007 CrossRefGoogle Scholar
- 16.Yu H, Yin L, Jiang X, Sun X, Wu J, Tian H, Gao X, He X (2014) Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies. PLoS ONE 9(12):e116327. https://doi.org/10.1371/journal.pone.0116327 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A, Szabo E (2014) Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) 7(9):867–885. https://doi.org/10.1158/1940-6207.CAPR-13-0424 CrossRefGoogle Scholar
- 20.Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, La Vecchia C, Mancia G, Corrao G (2012) Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 17(6):813–822. https://doi.org/10.1634/theoncologist.2011-0462 CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, Elasy TA, Griffin MR (2012) Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 157(9):601–610. https://doi.org/10.7326/0003-4819-157-9-201211060-00003 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Murff HJ, Elasy TA, Griffin MR (2014) Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA 311(22):2288–2296. https://doi.org/10.1001/jama.2014.4312 CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Haynes K, Beukelman T, Curtis JR, Newcomb C, Herrinton LJ, Graham DJ, Solomon DH, Griffin MR, Chen L, Liu L, Saag KG, Lewis JD, Collaboration S (2013) Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum 65(1):48–58. https://doi.org/10.1002/art.37740 CrossRefPubMedGoogle Scholar
- 27.S. V (2002) Flexible Imputation of Missing Data. CRC Press; Taylor and Francis Group, Boca RatonGoogle Scholar
- 28.Drugs and therapeutics committees: A practical guide (2003) World Health Organization. Department of Essential Drugs and Medicine Policy, GenevaGoogle Scholar
- 33.Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven K, Sacerdote C, Ashby D, Vineis P, Tzoulaki I, Ioannidis JP (2014) Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care 37(9):2522–2532. https://doi.org/10.2337/dc14-0584 CrossRefPubMedGoogle Scholar
- 37.Niesner K, Murff HJ, Griffin MR, Wasserman B, Greevy R, Grijalva CG, Roumie CL (2013) Validation of VA administrative data algorithms for identifying cardiovascular disease hospitalization. Epidemiology 24(2):334–335. https://doi.org/10.1097/EDE.0b013e3182821e75 CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Karlstad O, Starup-Linde J, Vestergaard P, Hjellvik V, Bazelier MT, Schmidt MK, Andersen M, Auvinen A, Haukka J, Furu K, de Vries F, De Bruin ML (2013) Use of insulin and insulin analogs and risk of cancer—systematic review and meta-analysis of observational studies. Curr Drug Saf 8(5):333–348CrossRefPubMedGoogle Scholar